2020
DOI: 10.1109/access.2020.2976544
|View full text |Cite
|
Sign up to set email alerts
|

Research on the Synergetic Innovation Between Pharmaceutical Enterprises and Scientific Research Institutions Based on the Quantum Game

Abstract: Synergetic innovation between pharmaceutical enterprises and scientific research institutions is extremely important for the development of innovative drugs. However, it is unstable in the pharmaceutical industry, which seriously hinders the development of innovative drugs in the World. China is the country with the biggest population, and therefore problems in this country are ones of the most important. In this context, we studied the influence of strengthening correlation degree on synergetic innovation bet… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 27 publications
0
2
0
Order By: Relevance
“…Recognising the need for synergies to deliver new solutions and systems, researchers tend to agree on the need for co-creation (Kumari et al 2020 ; Sharma and Sharma 2021 ), co-management (Léopold et al 2019 ; Casagrande et al 2021 ), and co-decisions for institutional resources (Shackleton and Raunio 2003 ). For instance, modern innovative drugs increasingly require co-development by pharmaceutical enterprises and scientific research institutions (Wang and Huang 2020 ). Thus, the complementary nature of institutions (Da Silva 2019 ), institutional roles (Garrick et al 2011 ) and institutional arrangements (Lee and Yoo 2008 ; Corsi and Prencipe 2019 ), serves as foci for some studies seeking to improve integration and accountability in institutions.…”
Section: Management Priorities For Institutional Innovationmentioning
confidence: 99%
“…Recognising the need for synergies to deliver new solutions and systems, researchers tend to agree on the need for co-creation (Kumari et al 2020 ; Sharma and Sharma 2021 ), co-management (Léopold et al 2019 ; Casagrande et al 2021 ), and co-decisions for institutional resources (Shackleton and Raunio 2003 ). For instance, modern innovative drugs increasingly require co-development by pharmaceutical enterprises and scientific research institutions (Wang and Huang 2020 ). Thus, the complementary nature of institutions (Da Silva 2019 ), institutional roles (Garrick et al 2011 ) and institutional arrangements (Lee and Yoo 2008 ; Corsi and Prencipe 2019 ), serves as foci for some studies seeking to improve integration and accountability in institutions.…”
Section: Management Priorities For Institutional Innovationmentioning
confidence: 99%
“…According to Jackson and Deeg (2008), the institutions will affect the investments. The decisions related to the firm's innovation and the regulation that allows interactions between the institutions depend on each country (Wang and Huang, 2020).…”
Section: Institutionsmentioning
confidence: 99%